PSMA-PET/CT分期寡转移前列腺癌的立体定向消融放疗:多中心研究
这项多中心回顾性病例系列纳入2015至2019年接受SABR的PSMA-PET/CT分期寡转移前列腺癌患者213例,中位随访57.6个月,36个月生化失败无生存率为18.8%,临床失败无生存率为39.2%,ADT无生存期中位41.98个月,5年ADT无生存率37.5%。
要点
- PSMA-PET/CT分期寡转移前列腺癌SABR后36个月生化失败无生存率18.8%。
- 36个月临床失败无生存率39.2%,中位ADT无生存期41.98个月。
- SABR可延缓治疗升级和ADT暴露超过3年。
核心结论
- 这是目前最大的PSMA-PET/CT分期寡转移前列腺癌接受SABR的队列,SABR可有效延缓治疗升级和ADT暴露超过3年。
研究设计与样本
- 多中心回顾性病例系列,纳入2015至2019年接受SABR的PSMA-PET/CT分期寡转移前列腺癌患者213例,允许同期ADT,排除SABR后12个月内接受原发灶放疗的同步转移患者。
主要发现
- 41.3%的SABR针对骨转移,49.3%针对淋巴结转移,28例(13.1%)SABR联合ADT,中位随访57.6个月(IQR 45.8-72.6)。
- 12、24、36个月生化失败无生存率分别为45.6%(95%CI 38.7-52.2%)、26.2%(95%CI 20.4-32.4%)、18.8%(95%CI 13.7-24.5%)。
- 12、24、36个月临床失败无生存率分别为71.4%(95%CI 64.7-77.0%)、50.4%(95%CI 43.4-57.1%)、39.2%(95%CI 32.4-45.8%)。
- 中位ADT无生存期41.98个月(95%CI 32.76-52.90),5年ADT无生存率37.5%(95%CI 29.8-45.1%)。
临床怎么用
- 对PSMA-PET/CT分期的寡转移前列腺癌患者,SABR可作为延缓ADT启动和治疗升级的转移导向治疗选择。
局限性
- 本研究为多中心回顾性病例系列,非随机对照设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Stereotactic ablative body radiotherapy (SABR) for oligometastatic prostate cancer (omPC) has proven a topic of emerging interest in the paradigm shift from palliative androgen deprivation therapy (ADT) to metastasis-directed therapy. In this study, we aim to evaluate and report on biochemical and clinical outcomes for omPC patients treated with SABR. METHODS AND MATERIALS: This was a multi-centre, retrospective case series of patients undergoing SABR for omPC from 2015 to 2019 inclusive, staged with PSMA-PET/CT. Concurrent ADT was permitted. Patients with synchronous metastatic disease receiving radiotherapy to primary within 12 months of SABR were excluded. The primary endpoint was biochemical failure-free survival (BCFFS). Secondary endpoints included: PSA response at 6 months, clinical failure-free survival (CFFS), defined by a 2nd course of SABR, commencing ADT, palliative radiotherapy, systemic therapy or changing current line of therapy; ADT-free survival (FS) was calculated in the SABR only cohort. RESULTS: 213 patients were included for analysis. 41.3 % of SABR was delivered to bone and 49.3 % to nodal metastases, with 28 patients (13.1 %) having SABR together with ADT. Median follow-up was 57.6 months (IQR 45.8-72.6). BCFFS at 12, 24 and 36 months was: 45.6 % (95 %CI: 38.7-52.2 %), 26.2 % (95 %CI: 20.4-32.4 %) and 18.8 % (95 %CI: 13.7-24.5 %), respectively. CFFS at 12, 24 and 36 months was: 71.4 % (95 %CI: 64.7-77.0 %), 50.4 % (95 %CI: 43.4-57.1 %) and 39.2 % (95 %CI: 32.4-45.8 %), respectively.Median ADT-FS was 41.98 months (95 %CI: 32.76-52.90), with 5-year ADT-FS reported at 37.5 % (95 %CI:29.8-45.1 %). CONCLUSION: This is the largest cohort of PSMA PET staged patients undergoing SABR for omPC, effective in delaying treatment escalation and ADT exposure beyond 3 years.
引用
- Schupak I, Chao M, Guerrieri M, et al. Stereotactic ablative body radiotherapy for PSMA-PET/CT staged, oligometastatic prostate cancer - A multi-centre study. Radiother Oncol. 2025. PMID: 41138859. doi:10.1016/j.radonc.2025.111219
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。